---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-090172"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T18:17:05.231300+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Invivyd reports positive Phase 1/2 data for VYD2311 COVID-19 mAb; half-life up to 76 days

## Summary
- All adverse events mild to moderate; no serious or severe AEs observed across IV, SC, and IM routes.
- VYD2311 half-life by cohort: IM 76 days, high-dose IV 61 days, vs pemivibart's 49 days.
- Dose modeling indicates IM dosing every 3 months may provide robust efficacy for immunocompromised and non-IC.
- Type C meeting with FDA scheduled for early Q3 2025 to discuss registration path for VYD2311.
- VYD2311 is 99%+ structurally identical to adintrevimab and pemivibart, with improved potency.

## SEC filing metadata
- accession: 0000950170-25-090172
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000095017025090172/0000950170-25-090172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000095017025090172/ivvd-20250626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-090172
- JSON: https://secwatch.observer/filing/0000950170-25-090172.json
- Plain text: https://secwatch.observer/filing/0000950170-25-090172.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.